Progressive familial intrahepatic cholestasis-2 and concomitant cytomegalovirus infection in an infant: a case report
DOI:
https://doi.org/10.18203/2349-3291.ijcp20221081Keywords:
PFIC-2, Cytomegalovirus, Neonatal cholestasis, Conjugated hyperbilirubinemiaAbstract
Conjugated hyperbilirubinemia (CH) in infancy can have anatomic, infectious, auto-immune and metabolic causes. We reported a case of CH presented at 2 months and 20 days, with clinical jaundice and evidence of acute on chronic liver failure. Significant history of elder sibling death at the age of 5 months due to hepatic failure and intracranial bleed was present. Investigations revealed a normal gamma glutamyl transpeptidase (GGT) levels. Toxoplasmosis, rubella, cytomegalovirus and herpes simplex (TORCH) panel showed cytomegalovirus (CMV) immunoglobulin M (IgM), immunoglobulin G (IgG) and deoxyribonucleic acid polymerase chain reaction (DNA PCR) positive with mother’s serum CMV IgG, so she was started on oral valganciclovir in addition to other treatment for cholestasis. A clinical exome panel was also sent which showed homozygous two base-pair deletion in exon 27 of the ABCB11 gene [c.3659 3660del (p.Ser1220Ter)] suggestive of benign recurrent intrahepatic cholestasis (BRIC)/progressive familial intrahepatic cholestasis-2 (PFIC-2). The child responded initially to treatment showing reduced serum conjugated bilirubin level and near normalization of INR. However, she was re-admitted with deranged coagulation profile and rising conjugated bilirubin levels after 30 days of discharge and expired due to fulminant hepatic failure with encephalopathy at 6 months of age while she was being prepared for live donor (father) liver transplantation. We presented this case because we found evidence of CMV infection in a child with PFIC-2. The relative contribution of either aetiology needs to be ascertained in view of early recurrence of CH despite standard management protocol including oral valgancyclovir for CMV infection.
References
Jacquemin E. Progressive familial intrahepatic cholestasis. Clin Res Hepatol Gastroenterol. 2012;36(1): 26-35.
Hasosah MY, Kutbi SY, Al-Amri AW, Alsahafi AF, Sukkar GA, Alghamdi KJ, et al. Perinatal cytomegalovirus hepatitis in Saudi infants: A case series. Saudi J Gastroenterol. 2012;18:208-13.
Agarwal S, Lal BB, Rawat D, Rastogi A, Bharathy KG, Alam S. Progressive Familial Intrahepatic Cholestasis (PFIC) in Indian Children: Clinical Spectrum and Outcome. J Clin Exp Hepatol. 2016;6(3):203-8.
Bilavsky E, Schwarz M, Bar-Sever Z, Pardo J, Amir J. Hepatic involvement in congenital cytomegalovirus infection - infrequent yet significant. J Viral Hepat. 2015;22(9):763-8.
Abolurin OO, Senbanjo IO, Adekoya AO, Ajibola ED. Congenital cytomegalovirus infection as an important cause of infantile cholestatic jaundice: a case report. Pan Afr Med J. 2020;36:106-8.
Engelmann G, Wenning D, Herebian D, Sander O, Dröge C, Kluge S, Kubitz R. Two Case Reports of Successful Treatment of Cholestasis with Steroids in Patients With PFIC-2. Pediatrics. 2015;135(5):1326-32.
Liu Y, Sun LY, Zhu ZJ, Wei L, Qu W, Zeng ZG. Liver Transplantation for Progressive Familial Intrahepatic Cholestasis. Ann Transplant. 2018;23:666-73.
Swed-Tobia R, Kassis I, Weiss K, Tal G, Shaoul R, Falik-Zaccai TC, Mandel H, Meir M. Concomitant congenital CMV infection and inherited liver diseases. Eur J Med Genet. 2021;64(8):104249.
